Sandoz Group (OTCMKTS:SDZNY) Sees Unusually-High Trading Volume – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) saw unusually-strong trading volume on Wednesday . Approximately 65,426 shares changed hands during mid-day trading, an increase of 112% from the previous session’s volume of 30,842 shares.The stock last traded at $83.78 and had previously closed at $82.65.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SDZNY. Royal Bank Of Canada cut Sandoz Group from a “moderate buy” rating to a “hold” rating in a research report on Monday, March 23rd. Jefferies Financial Group raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a research report on Wednesday, April 1st. Three equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy”.

Sandoz Group Stock Performance

The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.77 and a current ratio of 1.18. The company has a 50 day moving average of $81.38 and a 200 day moving average of $77.78.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.